Biofrontera Inc.
BFRIBiofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) for dermatological conditions.
Table of contents
Earnings
Next report
Aug 12, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) for dermatological conditions. The company's core value proposition centers on providing a highly effective, non-invasive treatment for actinic keratosis and other skin diseases through a proprietary combination of topical prescription drugs and specialized medical light sources. Following a strategic acquisition of U.S. rights, the company manages its own clinical development, manufacturing oversight, and direct sales to dermatology practices.
Biofrontera is a specialized player in the PDT market, positioning its Ameluz-PDT system as a 'gold standard' alternative to traditional cryotherapy and topical treatments for actinic keratosis.
Questions, answered.
- What is Biofrontera Inc.'s market cap?
- Biofrontera Inc. (BFRI) has a market capitalization of $14.6M and trades on NASDAQ.
- Who are Biofrontera Inc.'s competitors?
- Biofrontera Inc.'s key competitors include Soligenix, Inc. Common Stock, PUMA BIOTECHNOLOGY INC, Arcutis Biotherapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Biofrontera Inc. partner with?
- Biofrontera Inc.'s notable partners include Midas Pharma GmbH, Glaropharm AG, Pharbil Waltrop GmbH.
- What subsidiaries does Biofrontera Inc. have?
- Biofrontera Inc.'s subsidiaries include Discovery.
- Where is Biofrontera Inc. headquartered?
- Biofrontera Inc. is headquartered in United States of America and employs approximately 85 people. It has been publicly traded since 2021.